Business Development & Technology Transfer
CSHL is engaged in technology transfer as one way of delivering important discoveries to the public. Our Office of Technology Transfer actively supports our scientists to partner with companies, investors and others in order to achieve this mission and make a positive impact on society.
The purpose of CSHL’s technology transfer activities is to enable the scientific research conducted by our faculty, scientific staff and students to be developed and applied for the common good.To achieve this goal, we follow these guiding principles:
- Work collaboratively with CSHL scientists to support their aspirations, manage conflicts, comply with regulations and encourage synergy with CSHL’s mission
- Support effective dissemination of technology and leverage intellectual property rights and resources
- Encourage commercial opportunities with the potential to make a significant positive impact
- Engage with industry and investors to find the best partners to move ideas forward
- Negotiate fair and reasonable terms for deals that encourage commercialization, global access and good returns
The ultimate measure of our performance is the impact on society through our commercialization efforts. Early performance indicators include funds received, transactions entered into and relationships established and maintained.
Business Development & Technology Transfer News
- Cold Spring Harbor Laboratory and Deerfield Management Launch Harbor Discoveries to Advance New Therapeutics
- Envisagenics Announces Research Collaboration with Bristol Myers Squibb
- Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies
- Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform
- Envisagenics to Bring RNA Splicing Software Platform to J&J Lung Cancer Initiative
- Envisagenics Awarded $300K NCI Grant to Refine Drug Discovery Tech
- uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
- New technology could predict cancer outcome
CSHL and Deerfield Management launch Harbor Discoveries
January 12, 2023
Deerfield commits up to $130 million over 10 years to support drug development efforts.
Envisagenics and Biogen partner for RNA splicing research
June 9, 2021
CSHL spin-out company Envisagenics teams up with Biogen to advance research in RNA-based therapeutics for central nervous system diseases.
New incubator model for CSHL spin-outs
June 7, 2021
When a CSHL lab discovers a potential drug target, Autobahn Labs will collaborate with us to direct CRO work at Evotec funded by Samsara BioCapital.
$11 million investment to develop fibroblast therapeutic
April 26, 2021
CSHL Professor David Tuveson and other leading disease experts founded a company to target fibroblasts as a new way to treat cancer and inflammatory diseases.
CSHL tops Bush Center’s Innovation Impact Productivity Score
July 13, 2020
Cold Spring Harbor Laboratory ranks #1 in Innovation Impact Productivity Score among Pure Research/Health Care Institutions by the Bush Center.
Cold Spring Harbor Laboratory announces exclusive license with plant breeding start-up Inari
April 16, 2019
CSHL announced a licensing agreement with partner Inari, a company that is advancing plant breeding by tapping nature’s genetic diversity.
Breakthrough Prize laureates meet at CSHL
December 6, 2018
Breakthrough Prize winner Adrian Krainer & C. Frank Bennett reunite for the first time since their award ceremony at CSHL to discuss further project.
The case for open and inclusive science
June 8, 2018
America must continue to a place where the most talented people in the world want to live, study and work.
Andrew Whiteley appointed VP of Business Development and Technology Transfer at CSHL
April 3, 2018
Life science business leader Andrew Whiteley becomes the Vice President of CSHL's Business Development and Technology Transfer department.
Library of CRISPR targeting sequences increases power and accuracy of the gene-editing method
July 20, 2017
New library of RNA sequences that can be used by researchers to direct the CRISPR-cas9 complex to cut DNA with unprecedented precision.
Technology Transfer Process
Our Scientist’s Guide outlines key elements of the technology transfer process at CSHL. Learn more.
Engagement with industry and commercial relationships are governed by CSHL’s Commercial Relations Policy. Learn more.
If you are a CSHL scientist and think the results of your research have commercial potential, please come talk with us. We will discuss completing a Technology Disclosure Form and address any questions you have about our process. Learn more.
The exchange of research materials is an essential part of scientific research. It promotes effective collaboration among CSHL scientists and their counterparts in academia, government and industry. Learn more.
Conflict of Interest Policy
The Investigator Conflict of Interest Policy sets forth specific procedures for annual disclosure and review of significant financial interests so that, as an institution, the highest standards of integrity and objectivity are applied to the design, conduct and reporting of research carried out at or by CSHL. Learn more.
Consulting agreements are private contracts between investigators and companies outside the scope of CSHL employment. Investigators have an obligation to familiarize themselves with CSHL’s policies relevant to consulting activities before entering into any such arrangement. Learn more.
CSHL’s Faculty Guide provides an introduction to the areas of research interest for each member of our faculty.
CSHL’s world-renowned research programs span Cancer, Neuroscience, Plant Biology, Quantitative Biology and Bioinformatics & Genomics. CSHL’s research environment is highly collaborative, allowing CSHL scientists to work together across disciplines to solve biology’s most challenging problems, with the ultimate goal of benefiting the public by advancing this research to improve the diagnosis and treatment of cancer, neurological disorders and other diseases. With that goal in mind, CSHL grants licenses to existing and startup companies that demonstrate the technical and financial capabilities to develop our early-stage technology into commercially successful products. Companies are encouraged to discuss their business interests with our Office of Technology Transfer so we can bring the CSHL inventions and prominent investigators in their areas of interest to their attention. Learn more.
Material Transfer Agreements
The Office of Technology Transfer supports CSHL scientists with agreements to transfer proprietary materials into and out of CSHL through Material Transfer Agreements as well as tangible material licensing arrangements.
shRNA Technology Licenses
CSHL research has played a major role in developing short hairpin RNAs (shRNAs) as important biomedical research tools that we wish to see distributed and used broadly. Learn more.
CSHL’s preferred sponsored research arrangement with industry would follow our Uniform SRA format (pdf).
- Scientist Guide (pdf)
- Commercial Relations Policy (pdf)
- Invention Reporting Policy (pdf)
- Investigator Conflict of Interest Policy (pdf)
- Technology Evaluation Form (pdf)
- Technology Disclosure Form (pdf)
- Uniform Consulting Agreement Provisions (pdf)
- Uniform Sponsored Research Agreement (pdf)
- CSHL’s Faculty Guide
- AUTM Material Transfer Agreement Template (pdf)
- AUTM Briefing Book: Key Issues in the Technology Transfer Business (pdf)
- Guide to Consulting Agreements for Biomedical Scientists
- NIH Genomic Data Sharing Policy
The Office of Technology Transfer is located in the Luke Building.
General contact information
Business Development & Technology Transfer
Executive Assistant & Office Manager
Debra B. Arenare, J.D.
Vice President, General Counsel
Vladimir Drozdoff, Ph.D., J.D.
Chief Patent Counsel
Elizabeth A. Hand
Database, Accounting & Compliance Manager
Lindsey Karp, Ph.D.
Project Manager, Drug Discovery Projects
Cynthia R. Miller, J.D.
Radhakrishnan (“RK”) Narayanan, Ph.D., M.B.A.
Executive in Residence
Fahema Nadira, M.D.
Clinical Business Manager